Medical Device and Healthcare Industry Trends — 2026-06-08

Top 5 Headlines Today

• Korea’s medical device industry reaches 12.36 trillion won in 2025 production, up 8.1% with a 6-year trade surplus.
• MFDS designated 45 "innovative medical technologies" in 2025, a 50% increase year-over-year.
• FDA eases regulations on AI Clinical Decision Support (CDS) software and wearables (January 2026).
• Samsung unveils its next-gen Galaxy Watch AI Health Suite with major feature upgrades (June 4).
• GE HealthCare receives FDA 510(k) clearance for AI-based radiation therapy planning software (June 4).

Key Corporate Developments

Korean Medical Device Industry Overview

• The News: Domestic production hit 12.36 trillion won in 2025, an 8.1% increase, sustaining a 6-year trade surplus.
• Key Figures: 12.36 trillion won production; 6 consecutive years of trade surplus.
• Implication: Dental implants and ultrasonic diagnostic devices remain core exports. Korea’s global competitiveness is strengthening as the industry shifts rapidly toward high-value, innovative product categories.

Samsung Electronics Healthcare

• The News: Announced a new AI-based Health Suite for upcoming Galaxy Watch models, marking a major upgrade to existing health functions.
• Key Figures: New health app overhaul revealed June 2026.
• Implication: This is a strategic move by Samsung to align with FDA deregulation trends in AI and wearables, aiming to solidify its position in global digital health. Personalized, AI-driven services are set to be the key point of competition.

Classys Quarterly Performance

• The News: 2026 Q1 profit reached 8.72 billion won, up 13% year-over-year, bolstered by the acquisition of Brazilian distributor MedSystems.
• Key Figures: Q1 revenue of 8.72 billion won (13% increase); 42.7% operating profit margin.
• Implication: Domestic firms are successfully improving profitability through overseas expansion and M&A, accelerating their global network reach.

Policy and Regulation (MFDS)

Expanded Innovative Medical Technology Designations

• Details: The MFDS designated 45 products as innovative medical technologies in 2025, a 50% jump from the previous year.
• Focus: AI/big data-based devices, digital therapeutics, and wearable medical devices.
• Timeline: 2025 cycle complete; ongoing in 2026.
• Industry Impact: Clear support from the MFDS is expected to boost R&D investment for local startups. Faster approval paths will likely shorten time-to-market.

1 sources

koreabiomed.com

koreabiomed.com

GMP Audit Non-compliance: Sales Suspension Grace Period

• Details: Clarified criteria for applying sales suspension grace periods during GMP certification judgments for in-vitro diagnostic devices.
• Target: In-vitro diagnostic device manufacturers.
• Effective Date: March 2026 (revised notification).
• Industry Impact: While regulatory predictability improves due to clearer renewal procedures, the strict limits on grace periods increase the pressure on manufacturers to maintain tight approval schedules.

Market Immediate Entry System

• Details: Implementation of a conditional early market access system for innovative medical devices.
• Target: Devices with high innovation and clinical necessity.
• Effective Date: Officially launched January 26, 2026.
• Industry Impact: Represents a major improvement over existing approval systems, allowing for faster commercialization, though it requires more stringent post-market management.

Digital Health & AI

• GE HealthCare AI Software: MIM Contour ProtégéAI+ 2.0 received FDA 510(k) clearance (June 4). It enhances clinical efficiency in radiation oncology through automated treatment planning. Korean companies are developing similar AI solutions and must meet these emerging global standards.

• FDA CDS Regulation Ease: In January 2026, the FDA reclassified low-risk AI-based CDS and wearable features as general wellness/over-the-counter category items, significantly lowering entry barriers for Korean startups.

• Samsung Galaxy Watch AI Health Suite: New measurement and analysis features aim to boost market share in the wearable medical device space, aligning product strategy with global regulatory trends.

Global MedTech Context

• FDA AI/Wearable Deregulation: Offers Korean firms (such as Samsung, LG, Lunit, and Vuno) significant opportunities to shorten development and clinical timelines for the U.S. market.

• GE HealthCare 510(k) Milestone: The accelerated approval of AI medical devices by global giants provides a regulatory roadmap for Korean companies seeking FDA clearance for similar technologies.

• FDA TEMPO Pilot Program: The risk-based regulatory approach for chronic disease digital therapeutics (introduced Dec 2025) allows Korean developers more flexible review pathways when entering the U.S.

Investment, M&A, and Listing Trends

• Classys’ MedSystems Acquisition: Shows how buying overseas distributors directly contributes to profitability and regional networking.
• KOSDAQ Premium/Standard Tiering: The upcoming KOSDAQ split is expected to create opportunities for medical device firms (like Classys) to enter the "Premium" tier, while biopharma firms may face more relative difficulty.

Today's Insight

The Korean medical device industry has confirmed its competitive edge with a 6-year trade surplus, while FDA deregulation is acting as a catalyst for global expansion. The MFDS's increased focus on innovation (up 50%) and fast-track paths are shortening timelines for new entrants, though increased GMP standards add compliance burdens on existing manufacturers. Samsung’s AI Health Suite and Classys’ M&A success demonstrate that both large and mid-sized companies are finding clear, profitable paths to global competitiveness.

This Week’s Checkpoints

• Expected additional MFDS innovative medical technology designations in June (quarterly process).
• Monitor FDA PDUFA and 510(k) approval status.
• Official announcement on the KOSDAQ two-tier structure (expected in July).

Reader Action Items

• Manufacturers: Review the updated GMP audit grace period rules and audit your internal procedures.
• Startups: Review eligibility for MFDS innovative medical technology programs and explore the "Market Immediate Entry" system.
• Investors: Re-evaluate valuations of medical device companies poised for KOSDAQ "Premium" entry and watch for global M&A trends.